Aldeyra Therapeutics, Inc. (ALDX)
| Market Cap | 39.66M -86.9% |
| Revenue (ttm) | n/a |
| Net Income | -23.05M |
| EPS | -0.38 |
| Shares Out | 60.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 772,380 |
| Open | 0.6300 |
| Previous Close | 0.6206 |
| Day's Range | 0.6200 - 0.7180 |
| 52-Week Range | 0.5271 - 5.9300 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 6.60 (+903.8%) |
| Est. Earnings | Nov 17, 2026 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ALDX stock is "Buy." The 12-month stock price target is $6.6, which is an increase of 903.80% from the latest price.
News
Aldeyra Therapeutics Transcript: FDA announcement
A formal dispute resolution request will be submitted to contest the FDA's conclusion that reproxalap lacks sufficient evidence for effectiveness in dry eye disease. The appeal centers on the totality of evidence from nine clinical trials, with a decision expected in Q4 2026.
Aldeyra Therapeutics Press release: FDA announcement
Aldeyra Therapeutics issued a press release on September 29, 2026, disclosing material business information to investors.
Aldeyra Therapeutics Slides: FDA announcement
Aldeyra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Aldeyra to submit Formal Dispute Resolution Request to FDA for reproxalap
Aldeyra (ALDX) Therapeutics announced intent to submit to the U.S. Food and Drug Administration a Formal Dispute Resolution Request for reproxalap, an investigational drug candidate, for the treatment...
Aldeyra sees operational cash runway into 2029
Based on reported cash and cash equivalents of $45.1M as of June 30, 2026, Aldeyra (ALDX) updated financial guidance to include extension of operational cash runway into 2029. Published first…
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediat...
Aldeyra Therapeutics to Host Regulatory Update Webcast
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediat...
Aldeyra Therapeutics Quarterly report: Q2 2026
Aldeyra Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Levicept Appoints Darlene Deptula-Hicks as CFO
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens ...
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a late-stage dry eye disease program facing regulatory hurdles, with a pivotal FDA meeting and possible appeal ahead. Strong cash reserves, a robust pipeline, and a partnership with AbbVie position it for multiple near-term catalysts and long-term growth.
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims
A class action lawsuit was filed against Aldeyra Therapeutics ($ALDX) on March 30, 2026. Plaintiffs in the federal securities lawsuit allege that they acquired Aldeyra stock at artificially inflated p...
Aldeyra Therapeutics Quarterly report: Q1 2026
Aldeyra Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role o...
Aldeyra Therapeutics Proxy statement: Proxy filing
Aldeyra Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Aldeyra Therapeutics Proxy statement: Proxy filing
Aldeyra Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email...
ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (...
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from…
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focus...
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug application, or NDA, of reproxalap, an investigational drug candidate, for the treatment…
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
Aldeyra Therapeutics stock fell hard on Tuesday after it received a CRL from the FDA.
US FDA declines to approve Aldeyra's drug for eye disorder
The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said.
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...